Treating Patients With Melanoma and ALK Alterations With Ensartinib

Ensartinib will be given at a dose of 225mg daily in the form of 100mg and 25mg capsules. Patients will receive treatment continuously in 28 day cycles. Patients will then have the same tumor specimen biopsied again at day 15. Treatment will continue until disease progression, unacceptable toxicity, or patient choice to discontinue therapy.

a custom chip with probes targeting the ATI site in ALK, providing a reproducible, quantitative measure of ALKATI